Patents Assigned to G2 Inflammation Pty Ltd
  • Methods of inhibiting the interaction of C5aR with C5a with anti-C5aR antibodies
    Patent number: 8808701
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: August 19, 2014
    Assignee: G2 Inflammation Pty Ltd
    Inventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
  • Humanized Anti-C5aR Antibodies
    Publication number: 20130129721
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 23, 2013
    Applicant: G2 INFLAMMATION PTY LTD
    Inventor: G2 INFLAMMATION PTY LTD
  • Humanized anti-C5aR antibodies
    Patent number: 8361468
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: January 29, 2013
    Assignee: G2 Inflammation Pty Ltd
    Inventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
  • Anti-C5aR antibodies with improved properties
    Patent number: 8337852
    Abstract: The present invention relates to improved antibodies which bind to C5aR and which are useful in diagnosis and therapeutic methods.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: December 25, 2012
    Assignee: G2 Inflammation Pty Ltd
    Inventor: Charles Reay Mackay
  • Humanized anti-C5aR antibodies
    Patent number: 8268972
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: September 18, 2012
    Assignee: G2 Inflammation Pty Ltd
    Inventors: Peter Whitfeld, David Zahra, Charles Mackay
  • Method for producing antibodies
    Patent number: 8084024
    Abstract: The present invention relates to a method for producing antibodies and to antibodies produced by this method. In one embodiment the invention relates to a method for producing an antibody that binds to a polypeptide of a first species, the method comprising immunizing a mammal of a second species with cells derived from a transgenic mammal of the second species, wherein the polypeptide of the first species is expressed on the surface of the cells derived from the transgenic mammal.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: December 27, 2011
    Assignee: G2 Inflammation Pty Ltd
    Inventor: Charles Reay Mackay
  • Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use
    Patent number: 8071839
    Abstract: The present invention relates to transgenic non-human mammals comprising a polynucleotide encoding a human or humanized C5aR. The invention also relates to use of the transgenic non-human mammals in methods of screening for agonists, inverse agonists and antagonists of human C5aR and for testing efficacy of C5aR agonists, inverse agonists and antagonists in various animal models of disease.
    Type: Grant
    Filed: December 24, 2004
    Date of Patent: December 6, 2011
    Assignee: G2 Inflammation Pty Ltd
    Inventor: Charles Reay Mackay
  • Anti-C5aR Antibodies With Improved Properties
    Publication number: 20100129346
    Abstract: The present invention relates to improved antibodies which bind to C5aR and which are useful in diagnosis and therapeutic methods.
    Type: Application
    Filed: August 22, 2007
    Publication date: May 27, 2010
    Applicant: G2 INFLAMMATION PTY LTD.
    Inventor: Charles Reay Mackay
  • METHOD FOR PRODUCING ANTIBODIES
    Publication number: 20090312526
    Abstract: The present invention relates to a method for producing antibodies and to antibodies produced by this method. In one embodiment the invention relates to a method for producing an antibody that binds to a polypeptide of a first species, the method comprising immunizing a mammal of a second species with cells derived from a transgenic mammal of the second species, wherein the polypeptide of the first species is expressed on the surface of the cells derived from the transgenic mammal.
    Type: Application
    Filed: August 22, 2007
    Publication date: December 17, 2009
    Applicant: G2 INFLAMMATION PTY LTD.
    Inventor: Charles Reay Mackay